The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Chris Spivey is the editorial director of 

Articles

Highlights from a wide ranging discussion on COVID-19 pandemic response from Kate Broderick, Chief Innovation Officer at Maravai LifeSciences, and Tom Madden, President & CEO at Acuitas Therapeutics.

Unpacking COVID-19 Pandemic Response

Cheryl Barton is director of PharmaVision, 

What impact will EMA’s decision to phase out COVID-19 regulatory flexibilities have on the pharma industry?

Phasing Out COVID-19 Regulatory Flexibilities

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

EMA, the European Commission, and HMAs are phasing out the flexible regulations put into place during the pandemic.

Europe Phases Out COVID-19 Flexible Regulations

Full Marketing Authorization has been granted for Novavax’s COVID-19 vaccine by the European Commission.

COVID-19 Vaccine, Nuvaxovid, Gains EU Approval

The new guidelines contain formulation recommendations for vaccines launching in autumn 2023.

FDA Releases Updated COVID-19 Vaccine Guidelines

Podcasts

Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy. 

Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution

Paxlovid is not approved or authorized for use as a pre-exposure or post-exposure prophylaxis for prevention of COVID-19.

FDA Approves Paxlovid for Treatment of COVID-19 in Adults 

EMA and European regulators are lifting their COVID-19 business continuity measures as the pandemic’s peak ends.

Europe Lifts COVID-19 Business Continuity Status

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA is encouraging sponsors to conduct studies and file applications for full approval of products authorized by Emergency Use Authorizations.

FDA and Industry Prepare for End to COVID-19 Emergency

Editor of Pharmaceutical Technology Europe

Technological advances will help ease pressure on pharma supply chains, allowing for greater visibility and less uncertainty.

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success